Novo Nordisk Receives FDA Approval for Norditropin FlexPro 30 mg/3.0 mL for Patients with Growth Hormone Disorders

PLAINSBORO, N.J., Jan. 26, 2015 /PRNewswire/ --Novo Nordisk announced today the U.S. Food and Drug Administration (FDA) approval of Norditropin (somatropin [rDNA origin] injection) FlexPro 30 mg/3.0 mL, a prefilled injection pen for patients with growthhormone-related disorders. The FlexPro 30 mg/3.0 mL device complements the existing portfolio of Norditropin FlexPro products available in 5 mg/1.5 mL, 10 mg/1.5 mL and 15 mg/1.5 mL pens.

"Novo Nordisk is committed to advancing growth hormone delivery devices with patients in mind," said Eddie Williams, senior vice president, Biopharmaceuticals, Novo Nordisk. "This approval marks another option for patients who may need higher doses of treatment."

The availability of four different strengths of Norditropin FlexPro enhances physicians' ability to better address the unique needs of appropriate patients on treatment. Each Norditropin FlexPro pen is prefilled with Norditropin, and is color coded to differentiate the various strengths. Novo Nordisk plans to make Norditropin FlexPro 30 mg/3.0 mL available by April 2015.

Visit http://www.norditropin.comfor more information on Norditropin.

Indications and UsageWhat is Norditropin (somatropin [rDNA origin] injection)?

Norditropin is a prescription medicine that contains human growth hormone and is used to treat:

Important Safety InformationWho should not use Norditropin?Do not use Norditropin if:

What should I tell my healthcare provider before I start Norditropin?Tell your healthcare provider if you:

How should I use Norditropin?Do not share your Norditropin pen and needles with another person. You may give another person an infection or get an infection from them.

What are the possible side effects of Norditropin?Norditropin can cause serious side effects, including:

See original here:
Novo Nordisk Receives FDA Approval for Norditropin FlexPro 30 mg/3.0 mL for Patients with Growth Hormone Disorders